Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study

被引:23
作者
Niguma, T [1 ]
Mimura, T [1 ]
Tutui, N [1 ]
机构
[1] Okayama Saiseikai Gen Hosp, Dept Surg, Okayama 7008511, Japan
来源
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY | 2005年 / 12卷 / 03期
关键词
tumor thrombosis; adjuvant arterial infusion chemotherapy; hepatic arterial infusion chemotherapy; hepatocellular carcinoma;
D O I
10.1007/s00534-004-0969-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Purpose. The prognosis of hepatocellular carcinoma (HCC) with tumor thrombosis of the main trunk or major branches of the portal vein (mPVTT) is extremely poor, even if it is curatively resected. Uncontrollable multiple metastases to the residual liver are often observed within several months after the operation. We report here the results of a pilot study, showing the efficacy of adjuvant arterial infusion chemotherapy after the resection of HCC with mPVTT. Methods. Twelve patients had curative resection of HCC with mPVTT. Six of the patients were treated by the arterial infusion of a chemotherapeutic agent via a subcutaneously implanted injection port after curative resection of HCC with mPVTT. The initial course consisted of the daily administration of cisplatin (CDDP) and continuous infusion of 5-fluorouracil (5-FU). This was followed by the weekly or biweekly administration of CDDP and subsequent infusion of 5-FU until the cumulative dose of 5-FU reached 15 g. Results. The median overall survival time was 58.0 months with adjuvant chemotherapy and 8.0 months without adjuvant chemotherapy. The median disease-free interval was 15.0 months with adjuvant chemotherapy and 4.0 months without adjuvant chemotherapy. Adverse reactions were tolerable nausea and loss of appetite. Conclusions. This chemotherapeutic regimen achieved favorable results and may be useful as adjuvant chemotherapy in treating patients after curative resection of HCC with mPVTT.
引用
收藏
页码:249 / 253
页数:5
相关论文
共 41 条
  • [21] NELSON RS, 1966, CANCER, V19, P533, DOI 10.1002/1097-0142(196604)19:4<533::AID-CNCR2820190409>3.0.CO
  • [22] 2-6
  • [23] Okazaki N, 1986, Gan To Kagaku Ryoho, V13, P1584
  • [24] OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO
  • [25] 2-E
  • [26] Okuda K, 1999, ONCOL REP, V6, P587
  • [27] HEPATIC ARTERIAL INFUSION OF FLOXURIDINE, LEUCOVORIN, DOXORUBICIN, AND CISPLATIN FOR HEPATOCELLULAR-CARCINOMA - EFFECTS OF HEPATITIS-B AND HEPATITIS-C VIRAL-INFECTION ON DRUG TOXICITY AND PATIENT SURVIVAL
    PATT, YZ
    CHARNSANGAVEJ, C
    YOFFE, B
    SMITH, R
    LAWRENCE, D
    CHUANG, V
    CARRASCO, H
    ROH, M
    CHASE, J
    FISCHER, H
    JONES, D
    LEVIN, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) : 1204 - 1211
  • [28] BIOCHEMICAL MODULATION OF FLUOROURACIL - EVIDENCE OF SIGNIFICANT IMPROVEMENT OF SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA
    POON, MA
    OCONNELL, MJ
    MOERTEL, CG
    WIEAND, HS
    CULLINAN, SA
    EVERSON, LK
    KROOK, JE
    MAILLIARD, JA
    LAURIE, JA
    TSCHETTER, LK
    WIESENFELD, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (10) : 1407 - 1418
  • [29] Combined Intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches
    Sakon, M
    Nagano, H
    Dono, K
    Nakamori, S
    Umeshita, K
    Yamada, A
    Kawata, S
    Imai, Y
    Iijima, S
    Monden, M
    [J]. CANCER, 2002, 94 (02) : 435 - 442
  • [30] BIOCHEMICAL BASIS FOR CISPLATIN AND 5-FLUOROURACIL SYNERGISM IN HUMAN OVARIAN-CARCINOMA CELLS
    SCANLON, KJ
    NEWMAN, EM
    LU, Y
    PRIEST, DG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (23) : 8923 - 8925